Jyong Biotech Ltd. Ordinary Shares (MENS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jyong Biotech Ltd. Ordinary Shares (MENS) has a cash flow conversion efficiency ratio of 0.025x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-913.00K) by net assets ($-36.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Jyong Biotech Ltd. Ordinary Shares to measure how many days the company can operate on defensive assets alone.
Jyong Biotech Ltd. Ordinary Shares - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Jyong Biotech Ltd. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Jyong Biotech Ltd. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jyong Biotech Ltd. Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mercan Kimya Sanayi ve Ticaret AS
IS:MERCN
|
0.056x |
|
Kyeryong Const
KO:013580
|
0.114x |
|
Mosa Industrial Corp
TW:4564
|
-0.002x |
|
Agora S.A.
WAR:AGO
|
0.079x |
|
Payton Planar Magnetics Ltd
BR:PAY
|
0.079x |
|
Hurco Companies Inc
NASDAQ:HURC
|
0.019x |
|
GCL NEW ENERGY HD-0832
F:TJI
|
N/A |
|
OBI Pharma
TWO:4174
|
-0.132x |
Annual Cash Flow Conversion Efficiency for Jyong Biotech Ltd. Ordinary Shares (2020–2024)
The table below shows the annual cash flow conversion efficiency of Jyong Biotech Ltd. Ordinary Shares from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see Jyong Biotech Ltd. Ordinary Shares stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-36.52 Million | $-3.62 Million | 0.099x | +30.00% |
| 2023-12-31 | $-34.07 Million | $-2.60 Million | 0.076x | -23.87% |
| 2022-12-31 | $-29.63 Million | $-2.97 Million | 0.100x | +17.88% |
| 2021-12-31 | $-23.32 Million | $-1.98 Million | 0.085x | +50.27% |
| 2020-12-31 | $-19.20 Million | $-1.09 Million | 0.057x | -- |
About Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder … Read more